使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and thank you for standing by. Welcome to the GE HealthCare fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Please be advised this conference is being recorded.
大家好,感謝您稍候。歡迎參加 GE HealthCare 2024 年第四季及全年財報電話會議。(接線員指示) 請注意,本次會議將被錄音。
I would now like to hand the conference over to your speaker today, Carolynne Borders, please go ahead.
現在我想把會議交給今天的發言人 Carolynne Borders,請開始。
Carolynne Borders - Investor relations
Carolynne Borders - Investor relations
Thanks, operator. Good morning, and welcome to GE HealthCare's fourth quarter 2024 earnings call. I'm joined by our President and CEO, Peter Arduini; and Vice President and CFO, Jay Saccaro.
謝謝,接線員。各位早安,歡迎參加 GE HealthCare 2024 年第四季財報電話會議。今天與我一同出席的有我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Jay Saccaro。
Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website.
我們在本次電話會議中的發言將同時包含 GAAP 與非 GAAP 的財務結果。GAAP 與非 GAAP 指標之間的調節表可在今日新聞稿以及我們網站上的簡報投影片中找到。
During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties.
在本次電話會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們目前對情勢的看法。如我們向 SEC 提交的文件所述,實際結果可能因風險與不確定性而出現重大差異。
And with that, I'll hand the call over to Peter.
接下來,我把電話交給 Peter。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Thanks, Carolynne, and thanks to all those joining us today. At our Investor Day, we shared progress that we've made in executing on our precision care strategy since becoming an independent company. Now two years into our journey, I'm pleased to say that we're continuing on the path of strong execution with our fourth quarter results.
謝謝 Carolynne,也感謝今天所有與會者。在投資人日上,我們分享了自成為獨立公司以來,在執行精準照護策略方面所取得的進展。在我們旅程邁入第二年之際,我很高興地表示,從第四季的業績來看,我們仍持續走在強勁執行的軌道上。
In the quarter, we saw orders growth in every segment. We also saw a robust backlog and book-to-bill, the strongest since we became a public company.
本季我們看到各事業部門的訂單皆有成長。我們也看到強勁的在手訂單與出貨比(book-to-bill),為自我們成為上市公司以來最強。
We continued to see strength in the US market. For example, in a recent survey of US customers, half of those surveyed indicated they expected incremental imaging investment, particularly in the outpatient setting driven by expansion plans.
我們持續看到美國市場的強勁表現。例如,在近期一項針對美國客戶的調查中,受訪者有一半表示預期將增加影像設備投資,尤其是在門診場域,主要由擴張計畫所帶動。
In China, we're beginning to see a slight improvement in the market, evidenced by orders growth. This market is evolving in line with our previous commentary.
在中國,我們開始看到市場略有改善,從訂單成長可見端倪。該市場的演變與我們先前的評論一致。
We continued to deliver revenue growth driven by demand in our Advanced Visualization Solutions and Pharmaceutical Diagnostics businesses with overall strength in the US. For the total company, both sales volume and price were positive. In addition, sales and orders grew mid-single digits, excluding China in the fourth quarter.
我們持續實現營收成長,主要由先進視覺化解決方案(Advanced Visualization Solutions)與藥物診斷(Pharmaceutical Diagnostics)業務的需求所帶動,且美國整體表現強勁。就全公司而言,銷售量與價格皆為正向。此外,若排除中國因素,第四季銷售與訂單皆呈現中個位數成長。
We also continued to deliver robust margin expansion and earnings per share growth while investing in R&D. Our progress has been driven by our lean culture, creating better value for our patients and customers while delivering efficiencies across the business. We believe our commercial strategy, which is focused on securing highly strategic, long-term enterprise deals that help our customers deliver on their goals differentiates GE HealthCare.
在持續投入研發的同時,我們也持續帶來強勁的毛利率擴張與每股盈餘成長。我們的進展來自精實文化,在為病患與客戶創造更佳價值的同時,也在全公司推動效率提升。我們相信,我們的商業策略聚焦於取得高度策略性、長期的企業級合作案,協助客戶達成其目標,這使 GE HealthCare 脫穎而出。
What sets us apart is the way we bring together our holistic offering, which includes a comprehensive and integrated portfolio of AI-powered equipment, proprietary radiopharmaceuticals and services enabled by our digital capabilities.
我們的差異化在於能將整體性方案整合在一起,其中包含完整且整合的 AI 驅動設備組合、專有放射性藥物,以及由數位能力所賦能的服務。
In 2024, we closed 50 enterprise deals globally, laying a solid foundation for the future growth. And last month, we announced a Care Alliance with Sutter Health valued at $1 billion over seven years, bringing the total value to date of large deals closed and spend to over $5 billion. I'll talk more about this partnership and the impact of our enterprise strategy later in the call.
2024 年,我們在全球完成了 50 筆企業級合作案,為未來成長奠定堅實基礎。而在上個月,我們宣布與 Sutter Health 達成一項 Care Alliance,七年總值 10 億美元,使迄今已完成的大型合作案成交與支出總價值超過 50 億美元。我將在稍後的電話會議中進一步談到這項合作以及我們企業策略的影響。
Our commercial strategy supports our evolution from an imaging company to a health care solutions provider by working together with our customers to solve their greatest challenges. I'd like to share a few examples that illustrate this transformation.
我們的商業策略透過與客戶攜手解決其最重大挑戰,支持我們從影像公司演進為醫療照護解決方案供應商。我想分享幾個例子來說明這項轉型。
In 2024, we introduced approximately 40 innovations. Additionally, products launched within the last three years contributed to a strong new product introduction vitality of approximately 50% for the year. These high-margin NPIs reflect the impact of our increased R&D commitment and also help us drive recurring revenue. For example, our cath lab, Allia IGS Pulse is outperforming our expectations and we're on track to launch Flyrcado in the near term.
2024 年,我們推出約 40 項創新。此外,過去三年內上市的產品,為全年帶來約 50% 的強勁新產品導入活力(NPI vitality)。這些高毛利的新產品導入(NPI)反映了我們加大研發投入的成效,也有助於推動經常性收入。例如,我們的心導管室產品 Allia IGS Pulse 表現優於預期,而我們也正按計畫在近期推出 Flyrcado。
We continued to advance our leadership position in AI. In one year, we've gone from 58 to 85 AI-enabled FDA authorizations, one of the most in health care. To date, we've upgraded approximately 30% of our MR base with Air Recon DL and expanded Sonic DL to move beyond cardiac into other areas like brain and orthopedics. We're also making strides in the development of cloud-based solutions like CareIntellect to accelerate bringing clinical and operational applications to market.
我們持續推進在 AI 領域的領導地位。在一年內,我們的 AI 相關 FDA 核准/授權數從 58 項提升至 85 項,為醫療照護領域最多者之一。截至目前,我們已以 Air Recon DL 升級約 30% 的 MRI 裝機基礎,並擴展 Sonic DL,從心臟應用延伸至腦部與骨科等其他領域。我們也在雲端解決方案(如 CareIntellect)的開發上取得進展,以加速將臨床與營運應用推向市場。
And we're executing on our disciplined M&A strategy, complementing our existing technologies and solutions. Last year, we closed two acquisitions: MIM Software with AI-enabled image analysis and workflow tools and Intelligent Ultrasound, adding innovative real-time recognition technology. We also announced the planned acquisition of NMP to deepen our radiopharmaceutical distribution capabilities in Japan and other Asian markets.
同時,我們也在執行嚴謹的併購策略,以補強既有技術與解決方案。去年我們完成兩項收購:MIM Software(提供 AI 影像分析與工作流程工具)以及 Intelligent Ultrasound(加入創新的即時辨識技術)。我們也宣布計畫收購 NMP,以深化我們在日本及其他亞洲市場的放射性藥物配送能力。
Turning to our outlook for 2025. We introduced guidance for the year, which reflects healthy demand for our products and services in most of our markets globally, which is reflected in our orders growth. This guide is in line with our current view of the China market and the US tariffs on products from China.
接著談 2025 年展望。我們提出了全年指引,反映我們在全球多數市場的產品與服務需求健康,並體現在訂單成長上。此指引與我們目前對中國市場以及美國對中國產品加徵關稅的看法一致。
With that, I'll turn the call over to Jay to walk through our financial results for the fourth quarter and to provide more details on 2025 guidance.
接下來,我把電話交給 Jay,請他說明第四季財務結果,並提供更多 2025 年指引的細節。
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Thanks, Pete. Let's start with our financial performance on Slide 4. For the fourth quarter of 2024, we reported revenues of $5.3 billion with organic revenue growth of 2%, in line with our expectations. Global sales growth, excluding an approximate 200 basis points impact from China, was up 4% for the fourth quarter.
謝謝,Pete。我們先從第 4 頁投影片的財務表現開始。2024 年第四季,我們公布營收為 53 億美元,有機營收成長 2%,符合我們的預期。若排除中國約 200 個基點的影響,第四季全球銷售成長為 4%。
On a reported basis, service revenue grew 6% and product revenue was up 1%.Organic orders growth was 6% year-over-year driven by continued strength in the United States and across all segments. Order dollars continued to outpace sales, helping us deliver strong total company book-to-bill of 1.09 times, our highest since the spin.
以報表口徑計算,服務營收成長 6%,產品營收成長 1%。有機訂單年增 6%,主要由美國市場的持續強勁以及各事業部門的全面成長所帶動。訂單金額持續超越銷售,協助我們達成全公司強勁的出貨比(book-to-bill)1.09 倍,為分拆上市以來最高。
We exited the fourth quarter with a record backlog of $19.8 billion, up $700 million year-over-year and up $200 million sequentially. We continue to make excellent progress on margin, delivering an adjusted EBIT margin of 18.7%, up 260 basis points year-over-year due to productivity and volume.
我們在第四季結束時的在手訂單創下 198 億美元新高,年增 7 億美元,季增 2 億美元。我們在利潤率方面持續取得極佳進展,調整後 EBIT 利潤率達 18.7%,年增 260 個基點,主要受惠於生產力提升與銷量成長。
As a result, fourth quarter adjusted EPS was $1.45, up 23% year-over-year. Free cash flow of $811 million was down $145 million from last year.
因此,第四季調整後每股盈餘(EPS)為 1.45 美元,年增 23%。自由現金流為 8.11 億美元,較去年減少 1.45 億美元。
Turning to our full year results on Slide 5. For 2024, revenues of $19.7 billion grew 1% organically versus last year, in line with our guidance. On a reported basis, product revenue was flat and service revenue grew 3%. Recall that we grew 8% organically in 2023. Importantly, recurring revenue, which is more predictable and has attractive margins, represented more than 45% of total revenues for the year.
接著看第 5 頁投影片的全年結果。2024 年營收為 197 億美元,有機成長 1%,與我們的指引一致。以報表口徑計算,產品營收持平,服務營收成長 3%。請回想我們在 2023 年有機成長 8%。重要的是,較具可預測性且具吸引力利潤率的經常性收入,占全年總營收超過 45%。
Organic orders grew 3% year-over-year, and book-to-bill was 1.05 times. 2024 adjusted EBIT margin of 16.3% expanded 120 basis points year-over-year, ahead of our guidance, driven by productivity and price.
有機訂單年增3%,訂單出貨比(book-to-bill)為1.05倍。2024年調整後EBIT利潤率為16.3%,年增擴大120個基點,優於我們的指引,主要由生產力提升與定價所帶動。
Adjusted EPS of $4.49 also exceeded our guidance for the year, growing 14% year-over-year. In 2024, our adjusted EPS benefited by approximately $0.08 from onetime tax favorability related to completing our prior year global tax filings. Free cash flow of $1.6 billion was down $161 million year-over-year, which I'll cover later.
調整後每股盈餘(EPS)為4.49美元,也超出我們對全年之指引,年增14%。2024年,我們的調整後EPS約受益0.08美元,來自完成前一年度全球稅務申報所帶來的一次性稅務利多。自由現金流為16億美元,年減1.61億美元,我稍後會再說明。
On Slide 6, let's take a closer look at the strong progress we made on our margins in the fourth quarter and for the full year.
在第6頁投影片,讓我們更仔細看看第四季以及全年在利潤率方面取得的強勁進展。
Adjusted gross margin expanded 150 basis points versus the fourth quarter last year and 140 basis points versus the full year 2023. The increase in adjusted gross margin was a result of productivity improvements, including partnering with suppliers on material costs, design change improvements in our products and factory and service productivity. We also benefited from higher-margin new products.
調整後毛利率較去年第四季擴大150個基點,較2023年全年擴大140個基點。調整後毛利率的提升,來自生產力改善,包括與供應商合作降低材料成本、產品設計變更改善,以及工廠與服務端的生產力提升。我們也受益於毛利率較高的新產品。
As an example, in PDx, we held a multi-team Kaizen focused on improving the capacity on two of our critical manufacturing lines. By shortening changeover times, reducing wasted motion and prep time and implementing environmental health and safety actions, we added over 1 million annual patient doses of capacity. We also recognized productivity improvements of more than 20%.
例如,在PDx,我們舉辦了跨團隊的Kaizen(改善活動),聚焦於提升兩條關鍵製造產線的產能。透過縮短換線時間、減少不必要動作與準備時間,並落實環境、健康與安全(EHS)措施,我們新增了每年超過100萬劑病患用量的產能。我們也實現了超過20%的生產力提升。
For the fourth quarter, R&D investment was 6.5% of sales, up 9% year-over-year. For the full year, we invested $1.3 billion in R&D, equating to roughly 6.7% of sales, up from $1.2 billion in 2023. We remain committed to investing in innovation and developing unique technologies. We're also cultivating research collaborations that strengthen our leadership position in fast-growing areas such as theranostics, interventional cardiology among other growth opportunities.
第四季研發(R&D)投資占銷售額6.5%,年增9%。全年而言,我們投入13億美元於研發,約占銷售額6.7%,高於2023年的12億美元。我們仍致力於投資創新並開發獨特技術。我們也在培育研究合作,以強化我們在治療診斷(theranostics)、介入性心臟病學等快速成長領域的領導地位,以及其他成長機會。
On G&A, we've exited substantially all of our TSAs with GE further enabling us to optimize our cost structure today and into the future. I am really proud of all the teams who supported our transition to a stand-alone enterprise.
在一般與行政(G&A)方面,我們已與GE終止幾乎所有的過渡服務協議(TSA),進一步使我們能在當下及未來優化成本結構。我為所有支持我們轉型為獨立企業的團隊感到非常自豪。
Because of the actions I just mentioned, we delivered excellent improvement in adjusted EBIT margin, up 260 basis points in the fourth quarter and 120 basis points for the full year. These results, combined with our ongoing focus on execution and operational improvement give us confidence in our ability to deliver margin expansion into the future.
由於我剛才提到的各項行動,我們在調整後EBIT利潤率方面交出優異改善:第四季提升260個基點,全年提升120個基點。這些成果,加上我們持續聚焦於執行力與營運改善,讓我們對未來持續擴大利潤率的能力充滿信心。
Now I'll turn to our segments, starting with Imaging on Slide 7. Organic revenue in the quarter was flat versus the prior year. Strength in the US and rest of world was offset by headwinds in the China market. Segment EBIT margin was up 200 basis points year-over-year, driven by favorable price and product mix.
接下來我將談各事業部,先從第7頁投影片的影像(Imaging)開始。本季有機營收與去年同期持平。美國與世界其他地區的強勁表現,被中國市場的不利因素所抵銷。事業部EBIT利潤率年增200個基點,主要由有利的價格與產品組合所帶動。
The fourth quarter results capped a strong year of margin expansion for imaging with an improvement of 170 basis points on a total year basis due to progress with both productivity and price. We continue to see robust growth in the US as customers invest in innovation.
第四季的表現為影像業務強勁的年度利潤率擴張畫下句點;以全年計,利潤率改善170個基點,來自生產力與定價兩方面的進展。我們持續看到美國市場的強勁成長,因客戶正加大對創新的投資。
Turning to AVS on Slide 8. Organic revenue was up 4% year-over-year with increased sales volume in the US, partially offset by a decrease in China.
接著看第8頁投影片的AVS。有機營收年增4%,美國銷售量增加,部分被中國下滑所抵銷。
Segment EBIT margin increased by 240 basis points year-over-year, driven by continued productivity through standardization and volume as well as new product introductions. Sequentially, the strong improvement in margin versus the rest of 2024 was primarily due to volume leverage in the quarter.
事業部EBIT利潤率年增240個基點,主要由標準化與規模帶來的持續生產力提升,以及新產品導入所驅動。就季比而言,相較2024年其餘期間的利潤率大幅改善,主要來自本季的量能槓桿效益。
Customer demand for our AVS products remained robust, particularly in interventional cardiology and surgery like our OEC 3D platform.
客戶對我們AVS產品的需求仍然強勁,尤其是在介入性心臟病學與外科手術領域,例如我們的OEC 3D平台。
Moving to Patient Care Solutions on Slide 9. Organic revenue growth was flat versus prior year with services growth and improved fulfillment offset by a difficult comparison in monitoring solutions. Segment EBIT margin declined 50 basis points due to inflation and portfolio mix, partially offset by productivity actions. Sequentially, EBIT improved 220 basis points due to volume leverage.
接著看第9頁投影片的病患照護解決方案(Patient Care Solutions)。有機營收成長與去年同期持平;服務成長與履約改善,抵銷了監測解決方案面臨的高基期比較。事業部EBIT利潤率下滑50個基點,原因為通膨與產品組合影響,部分被生產力措施所抵銷。就季比而言,EBIT因量能槓桿提升220個基點。
As our portfolio mix normalizes and with continued productivity initiatives, we expect to drive improved margin performance. Strong global customer partnerships, particularly in the US, position us well for future growth.
隨著產品組合趨於正常化並持續推動生產力計畫,我們預期將帶動利潤率表現改善。強健的全球客戶夥伴關係,尤其在美國,使我們在未來成長上具備良好定位。
Moving to Pharmaceutical Diagnostics on Slide 10. We delivered another strong quarter, generating 9% year-over-year organic growth and EBIT margin of approximately 33%. We're pleased with this continued growth and margin expansion both year-over-year and sequentially.
接著看第10頁投影片的藥物診斷(Pharmaceutical Diagnostics)。我們再度交出強勁一季,實現有機成長年增9%,EBIT利潤率約33%。我們對這項持續的成長與利潤率擴張(無論年比或季比)感到滿意。
I would note that the year-over-year EBIT comparison was favorably impacted by onetime items including an investment related to in-licensing PET radiotracers in the fourth quarter of last year.
我想指出,年比EBIT的比較受到一次性項目的有利影響,其中包括去年第四季與引進授權(in-licensing)PET放射性示蹤劑相關的一項投資。
I also wanted to highlight that we recently announced a $138 million investment to expand our contrast media manufacturing facility in Cork, Ireland. This will create additional capacity to meet growing demand for contrast media while offering increased flexibility and supply resiliency.
我也想強調,我們近期宣布將投資1.38億美元,擴建位於愛爾蘭科克(Cork)的造影劑製造工廠。此舉將新增產能以滿足造影劑日益成長的需求,同時提升彈性與供應韌性。
Turning to cash flow on Slide 11. In the fourth quarter, we delivered healthy free cash flow of $811 million. This was down $145 million year-over-year due to inventory builds in 2024 that we expect to work down in the first half of 2025.
接著看第11頁投影片的現金流。第四季我們交出健康的自由現金流8.11億美元。由於2024年存貨增加(我們預期將在2025年上半年逐步去化),自由現金流年減1.45億美元。
Looking at the year, we're pleased with execution on our capital allocation initiatives. To strengthen our balance sheet, we paid down $400 million of debt in 2024 and an additional $250 million in the first quarter of 2025. We also executed on strategic M&A, including our purchase of MIM and Intelligent Ultrasound as well as our planned acquisition of NMP.
就全年來看,我們對資本配置計畫的執行感到滿意。為強化資產負債表,我們在2024年償還4億美元債務,並於2025年第一季再額外償還2.5億美元。我們也執行策略性併購(M&A),包括收購MIM與Intelligent Ultrasound,以及我們規劃中的NMP收購案。
Let's turn to our outlook on Slide 12. For 2025, we expect revenue growth in the range of 2% to 3%, which reflects continued demand for our products and services as well as our current view of market conditions in China.
接著看第12頁投影片的展望。對於2025年,我們預期營收成長介於2%至3%,反映對我們產品與服務的持續需求,以及我們目前對中國市場狀況的看法。
We're taking a measured approach that assumes China's sales performance will be negative in the first half of 2025 with a sequential improvement in the second half of the year versus the first half, leading to a low single-digit decline for the year. In addition, we expect a foreign exchange headwind to revenue to be approximately 1.5%.
我們採取審慎的假設:2025年上半年中國銷售表現將為負成長,下半年相較上半年將逐季改善,使全年呈現低個位數下滑。此外,我們預期匯率對營收的不利影響約為1.5%。
While the US tariff dynamic is fluid, we have incorporated the new China tariffs, which are in place today into our 2025 guidance. This impacts adjusted EBIT by approximately 10 basis points, assuming 11 months of impact. Therefore, we expect full year adjusted EBIT margin to be in the range of 16.7% to 16.8%, representing year-over-year expansion of 40 basis points to 50 basis points.
儘管美國關稅情勢仍在變動,我們已將目前已生效的新中國關稅納入2025年指引。在假設影響期間為11個月的情況下,這將使調整後EBIT約受影響10個基點。因此,我們預期全年調整後EBIT利潤率介於16.7%至16.8%,代表年增擴大40至50個基點。
Operationally, we remain committed to driving productivity initiatives and expanding margins. We're assuming an adjusted effective tax rate in the range of 22% to 23% for the full year. On adjusted EPS, we expect to deliver between $4.61 and $4.75 for the full year, representing 3% to 6% growth year-over-year. This includes approximately 1 point of impact from recently announced tariffs on products from China.
在營運面,我們仍致力於推動生產力計畫並擴大利潤率。我們假設全年調整後有效稅率介於22%至23%。在調整後EPS方面,我們預期全年將介於4.61至4.75美元,代表年增3%至6%。其中包含近期宣布對中國產品加徵關稅所帶來約1個百分點的影響。
Lastly, we expect to deliver free cash flow of at least $1.75 billion for the full year. For the first quarter of 2025, we expect organic revenue growth year-over-year to be in the range of 1% to 2% and adjusted EBIT margin and adjusted EPS to be approximately flat year-over-year.
最後,我們預期全年可交付至少 17.5 億美元的自由現金流。對於 2025 年第一季,我們預期有機營收年增率將落在 1% 至 2% 的區間,且調整後 EBIT 利潤率與調整後 EPS 預計將與去年同期大致持平。
When looking at the first half of 2025 versus the second half of the year, we expect organic revenue growth to be stronger in the second half of the year. As we move through the year, adjusted EBIT margin rate and adjusted EPS are expected to increase sequentially.
比較 2025 年上半年與下半年,我們預期下半年的有機營收成長將更為強勁。隨著年度推進,調整後 EBIT 利潤率與調整後 EPS 預計將逐季提升。
Overall, we're very proud of the work our teams contributed in 2024 to deliver on innovation and financial progress and we feel good about our guidance for 2025, especially with strong backlog and orders momentum.
整體而言,我們對團隊在 2024 年為推動創新與財務進展所做的工作深感自豪,並對 2025 年的財測指引感到樂觀,尤其是在強勁的積壓訂單與訂單動能之下。
Now, I'll turn the call back to Pete. Pete?
現在,我把電話交回給 Pete。Pete?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Thanks, Jay. As you've heard today and see on Slide 14, our NPIs launched in the last few years have appealed to customers, which translated into orders and revenue growth in 2024. This is another example of how we've made progress on our precision care strategy. We expect this to continue in 2025 and beyond.
謝謝,Jay。如同各位今天所聽到的、以及在第 14 頁投影片所看到的,我們在過去幾年推出的 NPI(新產品導入)受到客戶青睞,並在 2024 年轉化為訂單與營收成長。這是我們在精準照護策略上取得進展的另一個例證。我們預期這樣的趨勢將在 2025 年及往後持續。
We continue to evolve the way we think about innovation, which has always been a cornerstone for GE HealthCare. Innovation is so much more than the technology we create, it's about having a deep understanding of diseases and acting as a strategic partner for our customers rather than a transactional equipment vendor.
我們持續演進對創新的思維方式,而創新一直是 GE HealthCare 的基石。創新遠不止於我們所打造的技術;更在於對疾病有深刻理解,並作為客戶的策略夥伴,而非僅是一次性交易的設備供應商。
And by understanding the unique needs of each customer, we co-create a holistic offering, inclusive of technology, services and solutions and bring it all together in a cohesive way to drive transformation for the customer.
透過理解每位客戶的獨特需求,我們共同打造一套整體性的方案,涵蓋技術、服務與解決方案,並以一致且整合的方式將其串聯,推動客戶的轉型。
We began our long-term enterprise partnership strategy to deliver precision care when we became an independent company. A best-in-class example is of how it's taking hold in our recent announcement with Sutter Health, one of the largest integrated delivery networks in the US. Building on a 20-year relationship, Sutter Health chose us to help them transform the way they deliver care to their 3.5 million patients and create capacity to serve tens of thousands more across their network.
自我們成為獨立公司以來,便開始推動長期企業合作夥伴策略,以提供精準照護。一個同級最佳的例子,是我們近期與 Sutter Health 的公告,該機構是美國最大的整合式醫療服務網路之一,顯示此策略正在落地。在 20 年合作關係的基礎上,Sutter Health 選擇我們協助其轉型,改變其為 350 萬名病患提供照護的方式,並創造產能以在其網路中服務更多數以萬計的病患。
Another example is our long-term agreement with Nuffield Health in the UK to provide our latest advanced imaging and ultrasound equipment, technology upgrades and services over the next two decades. As the partner of choice, these agreements bring us the security of a multiyear commitment while increasing capacity and access of quality care for patients.
另一個例子是我們與英國 Nuffield Health 的長期協議,未來二十年將提供我們最新的先進影像與超音波設備、技術升級與服務。作為首選合作夥伴,這些協議在提升病患優質照護的產能與可近性的同時,也為我們帶來多年期承諾的穩定性。
We believe our ability to bring together a holistic offering of smart devices, drugs, digital solutions and services is differentiating and will result in more of these long-term partnerships accelerating recurring revenue growth.
我們相信,我們能整合智慧裝置、藥物、數位解決方案與服務的整體方案能力具備差異化優勢,並將促成更多此類長期合作夥伴關係,加速經常性收入成長。
In summary, on Slide 15, I'm proud of how our teams delivered in 2024 and what they do for patients every day. We continue to deliver solid results in revenue, margin, earnings and cash. And we're executing on our precision care strategy through commercial enterprise partnerships and investments in R&D to deliver innovation that solves the most pressing health care challenges for our patients and customers.
總結而言,在第 15 頁投影片上,我為我們團隊在 2024 年的交付成果,以及他們每天為病患所做的一切感到自豪。我們在營收、利潤率、獲利與現金方面持續交出穩健成果。我們也透過商業企業合作夥伴關係與研發投資,落實精準照護策略,提供能解決病患與客戶最迫切醫療挑戰的創新。
We're starting 2025 with strong momentum in orders, record backlog and book-to-bill and we're also on track to launch a number of exciting NPIs, including our proprietary radiopharmaceutical, Flyrcado. We've laid the groundwork for stronger sales conversion from orders, which positions us well for future growth.
我們以強勁的訂單動能、創紀錄的積壓訂單與出貨比(book-to-bill)展開 2025 年,同時也按計畫將推出多項令人振奮的 NPI,包括我們自有的放射性藥物 Flyrcado。我們已為由訂單轉化為銷售的更強轉換率奠定基礎,使我們在未來成長上具備良好定位。
All of that said, we're taking a measured approach to guidance as we start the year and see how the market dynamics, including China improvement and tariffs evolve. As a global company with a diversified supply chain and a significant US manufacturing base, we will continue to proactively work on potential mitigation plans.
儘管如此,年初我們在提供財測指引時仍採取審慎作法,並觀察市場動態如何演變,包括中國市場改善與關稅等因素。作為一家全球公司,擁有多元化供應鏈與顯著的美國製造基地,我們將持續主動推進潛在的因應與緩解方案。
Meanwhile, we're making good progress towards our total company medium-term financial targets. I'd also note that we are humbled to be recognized by Fortune as one of its world's most admired companies for 2025, and this is really a testament to the dedication of our 53,000 global colleagues to deliver every day for patients and customers.
同時,我們正朝向公司整體中期財務目標取得良好進展。我也想補充,我們很榮幸在 2025 年獲《Fortune》評選為全球最受推崇公司之一,這確實是對我們 53,000 名全球同仁每天為病患與客戶交付成果之奉獻精神的肯定。
Before we open up the call for questions, I'd like to take a few moments to share an organizational announcement. After more than 20 years with the company, Tom Westrick, President and CEO of Patient Care Solutions, has decided to retire from GE HealthCare. We expect to announce his replacement in the near future. Tom will remain with us to support a smooth transition, and I'd like to thank Tom for his contributions through the years and wish him all the best in his retirement.
在我們開放提問之前,我想花幾分鐘分享一項組織公告。在公司服務超過 20 年後,病患照護解決方案(Patient Care Solutions)總裁暨執行長 Tom Westrick 已決定自 GE HealthCare 退休。我們預期將在不久的將來宣布其接任人選。Tom 將繼續留任以支持順利交接;我也要感謝 Tom 多年來的貢獻,並祝福他退休生活一切順利。
And with that, let's open up the call for questions.
接下來,我們開放提問。
Carolynne Borders - Investor relations
Carolynne Borders - Investor relations
Thank you, Peter. (Event Instructions) Operator, can you please open the line?
謝謝你,Peter。(活動指示)接線員,請開放線路好嗎?
Operator
Operator
(Operator Instructions) Anthony Petrone, Mizuho Financial Group.
(接線員指示)Mizuho Financial Group 的 Anthony Petrone。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
Congratulations on a very strong overall print, record bookings, backlog and margin. And I think, Jay, I'm going to start off on the latter there on margin. And so maybe walk us through a little bit on the 18.7%, about 120 basis points above our model. But in particular, your LRP calls for high teens to low-20s. You're already in that range exiting 2024. That outlook was through 2028.
恭喜你們整體表現非常強勁,訂單創新高、積壓訂單與利潤率也都很亮眼。我想,Jay,我先從後者的利潤率談起。能否請你帶我們稍微梳理一下 18.7% 這個數字,大約比我們模型高出 120 個基點。但特別是,你們的 LRP(長期計畫)目標是高十位數到低 20% 區間。你們在 2024 年結束時就已經在這個區間內。而那個展望是到 2028 年。
So maybe just a little bit on the margin dynamics coming in ahead of expectations and how we should be thinking about that through the LRP? And I'll have one quick follow-up.
所以能否談談利潤率動能為何能超前預期,以及我們應該如何在 LRP 期間看待這件事?我還有一個簡短的追問。
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Sure. Thanks for the question, Anthony. We're very pleased with the progress that we're making on margin expansion. To your point, the margin in the fourth quarter was ahead of our expectations. But I think, notably, it was 260 basis points of expansion versus the prior year. 18.7% was a record for us.
當然。謝謝你的提問,Anthony。我們對利潤率擴張的進展感到非常滿意。如你所說,第四季的利潤率確實高於我們的預期。但值得注意的是,相較去年同期擴張了 260 個基點。18.7% 對我們而言是創紀錄的水準。
And as we look at the lines of the P&L, great performance on gross margin, 150 basis points or so. And then we also had declines in SG&A. We've talked about some of the work that we're doing to optimize this category and we were able to deliver on that in the fourth quarter.
從損益表各項目來看,毛利率表現非常出色,約提升 150 個基點。此外,SG&A(銷售、一般及行政費用)也有所下降。我們先前談過正在進行一些工作以優化這個類別,而我們在第四季也做到了。
As we think about specific drivers of the result, we saw a benefit from volume, mix and price all contributing. It was approximately 150 basis points of EBIT margin expansion from those categories. And then, interestingly, from a variable cost productivity program and savings initiatives, all of that good work that we're doing fully offset any inflation or inefficiencies that we saw. So all of the price, volume, mix was able to flow through unimpacted.
就結果的具體驅動因素而言,我們看到出貨量、產品組合與價格皆有貢獻。這些類別合計帶來約 150 個基點的 EBIT 利潤率擴張。另外,有意思的是,透過變動成本生產力計畫與節省措施,我們所做的所有努力完全抵銷了我們看到的任何通膨或效率不彰。因此,價格、出貨量與組合的效益得以不受影響地反映到利潤率上。
Now, I will tell you we had about 100 basis points of onetime items. Some of which we had anticipated, some of it relates to spend from last year that was not repeated this year, some of it was related to foreign exchange. And so in combination, that was about 100 basis points. But really, this was just an overall really solid performance.
我也要說明,我們約有 100 個基點的一次性項目。其中一部分是我們原先就預期到的;一部分與去年發生、今年未再重複的支出有關;還有一部分與外匯有關。合計約為 100 個基點。但整體而言,這就是一次非常扎實的表現。
We talk extensively about the lean culture and what we're trying to do. And there's a lot of elements to that like safety, quality and delivery, but this idea of lean's impact on cost, I think, was very solid in the fourth quarter.
我們廣泛討論精實文化以及我們試圖達成的目標。其中包含許多要素,例如安全、品質與交付,但我認為精實對成本的影響這個概念在第四季表現得非常扎實。
Now as we look to the midterm, it's important not to extrapolate off of fourth quarter because seasonally fourth quarter is always, by far, the highest margin of the year. And so we'll see a return to normalcy in the first quarter as we look to have a nice solid margin expansion in 2025.
現在當我們展望中期時,重要的是不要以第四季為基礎去外推,因為從季節性來看,第四季一向是全年毛利率最高的季度,且幅度遠高於其他季度。因此,第一季我們將看到回歸常態,而我們也預期在2025年能有良好且穩健的利潤率擴張。
But I do think it's safe to say we're increasingly confident in our ability to deliver margin from the business. So no change to midterm guidance. We did -- on the Investor Day, we said we think there's an opportunity to deliver 20%-plus over time. And that plus was an important addition for us. I think this fourth quarter print gives us more confidence in that plus.
但我確實認為可以很有把握地說,我們對於從業務中實現利潤率的能力愈來愈有信心。因此,中期指引沒有變動。我們在投資人日曾表示,隨時間推進,我們認為有機會達到20%以上。而這個「以上」對我們而言是很重要的補充。我認為第四季的成績讓我們對這個「以上」更有信心。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
That's very helpful. And the quick follow-up would just be you're facing -- I'll stick to margin, let others jump in. You're facing the pressures in China. You have some FX, you mentioned inflation. Let's assume inflation stays there. But if we have normalization in China, is it fair to say that this could be an upside case to the mid-20s on the margin side over time.
這非常有幫助。我快速追問一下,我就聚焦在利潤率,讓其他人接著問。你們正面臨中國的壓力。也有一些匯率因素,你提到通膨。假設通膨維持在目前水準。但如果中國情況正常化,是否可以說,長期來看利潤率有機會上行到20%中段(mid-20s)的情境?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
I think we'll stop with resetting the midterm guidance. But I think it's safe to say, amidst -- if you look at last year's full result, 120 basis points despite very low sales growth and despite some unplanned market volatility. And then we fast-forward to this year, we're talking about sales growth that's below the midterm expectations. And despite that, we're delivering another 40 basis points to 50 basis points of margin expansion.
我想我們就先不重新設定中期指引。但我認為可以很有把握地說,若看去年的全年結果,在銷售成長非常低、且有一些非預期的市場波動之下,我們仍然提升了120個基點。然後快轉到今年,我們談的是低於中期預期的銷售成長。即便如此,我們仍能帶來另外40到50個基點的利潤率擴張。
So we feel really good about our opportunities to drive this going forward. And I think some of the excitement around innovation and all those products coming to market those should only bolster performance.
因此,我們對未來推動這件事的機會感到非常樂觀。而且我認為,圍繞創新以及所有這些產品上市所帶來的興奮感,只會進一步強化表現。
Pete, what would you add?
Pete,你會補充什麼?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
I think you covered it, Jay. But Anthony, to your question, I think just as we went through the Investor Day and we talked about 20%-plus, part of that is we're right on track to where we had expected to be when you take a look at the growth rate and where we're expecting to be here for this year.
我想你都涵蓋到了,Jay。不過Anthony,回到你的問題,我認為就像我們在投資人日談到的20%以上,其中一部分是:當你看成長率以及我們預期今年會到達的位置時,我們正好符合當初的預期進度。
And then if you recall, a lot of our launches come out in '26 and a big focus on having those at higher value prices than the segments that they're in and also higher gross margins. And again, that's been a critical part of our strategy from the beginning, platforming and such. And so it's good to see that coming through.
另外,如果你還記得,我們很多產品會在26年推出,而重點之一是讓這些產品在其所屬細分市場中以更高的價值定價,同時也帶來更高的毛利率。而且再次強調,這從一開始就是我們策略的關鍵部分,包括平台化等。所以看到這些逐步反映出來是件好事。
Operator
Operator
Craig Bijou, BofA Securities.
Craig Bijou,BofA Securities。
Craig Bijou - Analyst
Craig Bijou - Analyst
Want to start with China and maybe just see if you could elaborate on some of your comments on the order environment in China in Q4. And then, Pete, you've been helpful in the past talking about some of the work that you guys have done province by province to understand where each province is in the stimulus process.
我想先從中國開始,請你們再多闡述一下對於第四季中國訂單環境的評論。另外,Pete,你過去談到你們逐省(province by province)所做的工作,去了解各省在刺激措施流程中的進度,這些分享一直很有幫助。
So just wanted to see if you can maybe provide some updated insight at the various stages for each province? And then I'll have a follow-up.
所以想請你也許能提供各省在不同階段的最新洞見?然後我還有一個追問。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, Craig, thanks for the question. I mean, I would start out just at a high level and say, fundamentally, what we said at Investor Day and what we've been communicating in between is on track to what our expectations are. We expected to see some improvement of orders. Again, it's off of a challenging base the previous year, but that actually took place.
好的,Craig,謝謝你的問題。我想先從高層次來說,基本上,我們在投資人日所說的,以及之後持續對外溝通的內容,都符合我們的預期。我們原本就預期訂單會有一些改善。再次強調,這是建立在前一年較具挑戰的基期之上,但確實發生了。
And so again, from the standpoint of anticorruption and then stimulus and the movement going forward on that, we've looked at this across all the provinces. And we've talked in the past about the different steps in the process.
因此,再次從反貪腐、刺激措施,以及後續推進的角度來看,我們已在所有省份進行檢視。而我們過去也談過流程中的不同步驟。
And again, I would say at this point in time, it is on track to what we had laid out before, which is start seeing more orders improvement in the first half, starting at later Q1, starting to see some of that in Q2, maybe having some benefits in the latter part of Q2. But the majority of the sales translation of orders would be more in the second half.
同樣地,我會說就目前而言,進度符合我們先前所規劃的:在上半年開始看到訂單改善,從第一季後段開始,第二季開始看到一些跡象,可能在第二季後段帶來一些效益。但訂單轉化為銷售的主要貢獻會更多落在下半年。
I don't know if Jay can comment a little bit more as well about it from what we said on the guide, but I -- from what we see things right now, they're on track to line up to exactly to that. Jay, what would you add to the China question?
我不確定Jay是否也能就我們在指引中所說的再補充一些,但就我目前看到的情況,它們正按部就班,完全符合那樣的節奏。Jay,你對中國的問題會補充什麼?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
No, I think that's right. We were encouraged to see orders growth in the fourth quarter. But as we kind of look forward, we're anticipating negative growth in the first half of 2025. And then we'll see some sequential improvement in the second half versus the first half.
沒有,我認為你說得對。我們很受鼓舞地看到第四季訂單成長。但往前看,我們預期2025年上半年會是負成長。然後下半年相較上半年會看到一些逐季改善。
So overall, in our numbers, we're anticipating a low single-digit revenue decline for the year. We'll watch this very carefully. As we've said previously, we think China is an attractive long-term market. But clearly, there's been some volatility. So we've reflected that thinking in the guidance that we've shared here.
因此整體而言,在我們的數字中,我們預期全年營收會有低個位數的下滑。我們會非常密切地觀察。如同我們先前所說,我們認為中國是具吸引力的長期市場。但顯然,波動一直存在。所以我們已在這裡分享的指引中反映了這樣的看法。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
And I've, in the past, used a simple kind of four process step about provinces announce that they have the money, they'll announce a tender, they'll grant the order and then you'll ship it. I mean, we're pretty much aligned to that kind of in step 2, the tenders are starting to take place. And again, I think our guidance is very much aligned to how we think this is going to roll out for the year.
而我過去用過一個簡單的四步流程來描述:各省宣布他們有資金、接著宣布招標、然後授予訂單,最後你才出貨。我們目前大致上與這個流程對齊在第2步,也就是招標開始發生。同樣地,我認為我們的指引非常符合我們對今年推進節奏的判斷。
Craig Bijou - Analyst
Craig Bijou - Analyst
Got it. That's helpful. And just thinking about the hospital CapEx environment in the US and around the world, it sounds like you guys see a pretty solid market or environment. So I guess, I wanted to ask if that is true.
了解。這很有幫助。再來談到美國以及全球的醫院資本支出(CapEx)環境,聽起來你們認為市場或環境相當穩健。所以我想問,是否確實如此。
And then maybe just touch on some of the competitive dynamics in the markets? I know one of your competitors recently talked about competitive wins. So would love to hear what you're seeing on the competitive front as well as the overall market environment.
另外也請談談市場中的一些競爭動態?我知道你們的一家競爭對手最近提到一些競爭性勝出(competitive wins)。所以也很想聽聽你們在競爭面以及整體市場環境上看到的情況。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. I would say, Craig, look, from a CapEx standpoint, ex the China discussions we just made, we see improvements pretty much around the world. I would say I'd start with Europe and say Europe was a more challenging year last year.
是的。Craig,我會說,從資本支出的角度來看,撇除我們剛才談到的中國議題,我們看到全球幾乎都在改善。我會先從歐洲談起,歐洲去年是比較具挑戰的一年。
I think we had mentioned in some previous comments about government changes that people put pauses on and took a look at things. We would expect to start seeing that moving in a more positive direction here in '25.
我想我們在先前的一些評論中提到過,因為政府更迭,有些人先按下暫停鍵、重新檢視一些事情。我們預期在25年會開始看到情況朝更正面的方向發展。
In the United States, it was a strong year. And again, as hospital systems retool, probably one of the oldest installed bases around different countries around the world, we're seeing again that upgrade taking place. And what underpins that, which is happening around the world, but more so in the US is just strong growth of procedures, which I know you guys all see in some of the device companies.
在美國,這是一個表現強勁的一年。而且再次地,隨著醫院體系進行設備更新改造——在全球不同國家中,可能擁有最老舊的既有裝機基礎之一——我們再次看到升級正在發生。而支撐這一點的因素(這在全球都在發生,但在美國更為明顯)就是手術量的強勁成長,我知道你們在一些醫療器材公司那邊也都看得到。
Interventional procedures up strong double digits, surgical procedures moving to outpatient centers, requiring ultrasound and C-arms, those are a lot of the things that we're seeing the benefit and we believe are going to continue. The need against -- for cath labs to handle many of the growth in structured heart and orthopedic procedures as an example. So from that standpoint, that's kind of the marketplace.
介入性手術量以強勁的雙位數成長,外科手術轉往門診中心,因而需要超音波與C臂,這些都是我們正在看到受益、並且相信將會持續的因素。例如,心導管室(cath labs)需要具備能力來承接結構性心臟與骨科手術等多項程序的成長。所以從這個角度來看,這大致就是市場狀況。
You asked about the competitive environment. Obviously, from a China standpoint, it's obviously been a very strong competitive market with local players as well as multinationals, but we feel quite confident in how we've laid out our ability to win.
你問到競爭環境。很明顯地,從中國的角度來看,這一直是競爭非常激烈的市場,既有本土業者也有跨國公司,但我們對於我們所規劃的致勝能力相當有信心。
And I would say when you take a look at the markets around the world, we tend to be a little bit stronger in the US than maybe we are in Europe just based on us being the US -- largest US imaging company. But we believe we're doing quite well in each of the segments.
我會說,當你放眼全球各市場,我們在美國通常會比在歐洲更強一些,這主要是因為我們是美國——最大的美國影像公司。但我們相信我們在各個細分領域的表現都相當不錯。
I would kind of harken back to our Investor Day to say, look, we have a new product coming out in CT that we'll be on track to launch and discuss next year. We have an evolution in our molecular imaging pipeline with a full-body PET that will be coming out.
我會回到我們的投資人日來說明:我們在CT方面有一款新產品即將推出,我們會按計畫在明年上市並進一步討論。我們的分子影像產品線也在演進,將推出一款全身PET。
And so in certain areas there, I think some of our players are actually converting some of their own installed base, which is helping some of their growth. But we feel very confident that across our installed base, and in many cases, exemplified in some of the larger wins, we're doing quite well.
因此在某些領域,我認為有些競爭對手其實正在把自家既有裝機基礎進行替換升級,這也在幫助他們的成長。但我們非常有信心,無論是在我們的既有裝機基礎上,或是在一些大型得標案所展現的成果上,我們的表現都相當不錯。
You add in those new products in the coming years, those are, again, as I mentioned, at Investor Day is worth 1 points to 2 points of additional growth from the new products that are going to be coming out.
再加上未來幾年將推出的那些新產品——如我在投資人日提到的——新產品帶來的額外成長約可貢獻1到2個百分點。
Operator
Operator
Vijay Kumar, Evercore ISI.
Vijay Kumar,Evercore ISI。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
Maybe, Jay, one on guidance question here. The 2% to 3% organic, I think, ex-China, it's rounded to something like 2.5% to 3.5%. If I look at your capital book-to-bill, it was close to 1.1x in fiscal '24. I think you ended the year at 1.16%.
Jay,這裡有一個關於財測的問題。2%到3%的有機成長,我想若排除中國,四捨五入大概是2.5%到3.5%。如果我看你們的資本設備出貨比(book-to-bill),在2024財年接近1.1倍。我想你們年末是1.16%。
Why is 2.5% to 3.5%, like ex China, the right number when Q4 -- you exited Q4 at 4% organic. What is the guide assuming for volume versus price in Flyrcado?
為什麼排除中國後2.5%到3.5%會是合理的數字?因為第四季——你們在第四季退出時有機成長是4%。在Flyrcado方面,這個指引假設的量與價各是什麼?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Sure. Thanks for the question. So overall, as you say, we have China down low single digit on a full year basis. And so excluding China, you get close to the mid-single-digit midterm aspiration. And I will tell you, we were very encouraged with the order performance in the fourth quarter, 6% with a very attractive book-to-bill is exactly where we hope to end the year and we were able to deliver on that.
當然。謝謝你的問題。整體來說,如你所說,我們全年基礎下中國是低個位數下滑。因此排除中國後,就會接近我們中期目標的中個位數水準。我也想說,我們對第四季的訂單表現非常受到鼓舞:訂單成長6%,且出貨比非常吸引人,這正是我們希望在年底達到的狀態,而我們也做到了。
A lot of that has to do with a buoyant capital environment, as Pete described, and a lot of it has to do with great performance from the team. As we think about, though, the sales guidance, a lot of those orders have delivery dates either in the second half of this year or into next year.
這很大一部分來自如Pete所描述的活絡資本環境,也有很大一部分來自團隊的優異表現。不過當我們思考營收指引時,許多訂單的交付日期是在今年下半年或延伸到明年。
And so from our standpoint, while that's a very, very encouraging sign, it's not something that impacts Q1 or Q2 revenues, and so important for us to be very thoughtful about when those deliveries take place and how things work as it relates to guidance of the year.
因此從我們的角度來看,雖然這是非常、非常令人鼓舞的訊號,但它不會影響第一季或第二季的營收,所以我們必須非常審慎地考量這些交付何時發生,以及這些因素如何影響全年指引。
So what I would say is from a fourth quarter standpoint, the record backlog that we put in place, the high book-to-bill along with the orders growth gives us increasing confidence as we look at the health of the business. And I think we've reflected that with a reasonable guidance for this year. Pete, anything to add?
所以我要說的是,從第四季的角度來看,我們創下的歷史新高在手訂單(backlog)、較高的出貨比,以及訂單成長,都讓我們在評估業務健康度時更有信心。我想我們也用今年合理的指引反映了這一點。Pete,有沒有要補充的?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
I think you covered it, Jay. I think you covered it. I mean, you mentioned -- you raised the question about Flyrcado, Vijay. We feel really good about where we are, just to be clear. We're on track to our launch. I think we've referenced before first dosing here within the first quarter and then ultimately launch beginning of April. We're well on track to that.
我想你已經涵蓋了,Jay。我想你已經涵蓋了。我是說,你提到——你問到Flyrcado,Vijay。我們對目前的進展感覺非常好,先說清楚。我們的上市進度按計畫進行。我想我們之前提過,第一季內會進行首次給藥(first dosing),然後最終在4月初上市。我們完全按計畫推進。
And at this point in time, we're assuming in our plans roughly around $30 million of revenue for the year.
而在目前這個時間點,我們在計畫中假設今年大約有3,000萬美元的營收。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
That's helpful, guys. And maybe one more guidance-related question, Jay. Q1, I think I heard you say flat margins. Is there anything one-off in Q1? I mean, is that sort of a gross margin impact? Or is this an OpEx line item, which would drive the flat margins?
這很有幫助,謝謝各位。再問一個與指引相關的問題,Jay。第一季,我想我聽到你說利潤率持平。第一季有任何一次性因素嗎?我的意思是,這是毛利率的影響嗎?還是這是營業費用(OpEx)的項目,導致利潤率持平?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
In the first quarter, we're going to -- we'll expect to see a little bit of gross margin improvement and a little of OpEx investment. The interesting thing that's happening is we have a lot of exciting launches coming. So we have to make sure from an R&D standpoint, we're funding those for success, some crucial programs with crucial milestones coming this year. So that investment is coming to bear in the first quarter.
在第一季,我們預期會看到毛利率小幅改善,同時也會有一些營業費用投資。目前有趣的是,我們接下來有很多令人振奮的新產品上市。因此從研發角度,我們必須確保資金到位以支持成功,因為今年有一些關鍵專案與關鍵里程碑即將到來。所以這些投資會在第一季開始反映出來。
And then secondly, from an SG&A standpoint, we're excited about this Flyrcado launch and a number of other launches that are taking place across the company. But that does require having adequate investment. We don't want to underclub the investments in any of these crucial new product launches.
第二,從銷售、一般及行政費用(SG&A)的角度來看,我們對Flyrcado的上市以及公司內其他多項上市計畫感到興奮。但這確實需要足夠的投資。我們不希望在任何這些關鍵新產品上市上投資不足。
So you're going to see a little bit of offsets from an OpEx standpoint to gross margin expansion, leading to the margin that we've described in the first quarter.
因此你會看到在營業費用端對毛利率擴張形成一些抵銷,最終導致我們所描述的第一季利潤率表現。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
So Vijay, just a simple example is, obviously, we're expanding our cardiology PET call points. So we're adding sales force marketing to be prepared for the launch. That would be an investment in the first half that's part of -- built into that profit number.
所以Vijay,舉個簡單例子,顯然我們正在擴大心臟科PET的拜訪點(call points)。因此我們會增加銷售團隊與行銷資源,以為上市做好準備。這會是上半年的一項投資,並已納入那個獲利數字之中。
Operator
Operator
Matt Taylor, Jefferies.
Matt Taylor,Jefferies。
Matt Taylor - Analyst
Matt Taylor - Analyst
I noticed you talked about the order growth being up across the segments. And I guess I was wondering if you could help us a little bit more with any segment color in terms of the growth expectations for 2025, and particularly on PDx given the Flyrcado commentary you just gave?
我注意到你提到各個事業部的訂單成長都有上升。我想請你能否再多提供一些分部層面的資訊,談談2025年的成長預期,特別是就PDx而言,考量你剛才對Flyrcado的評論?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Yeah. I think we were definitely pleased to see the order strength across the Board. It was one of -- a rare quarter when every single business saw consistent orders growth. So that was really great. And on a full year basis, I think, robust.
是的。我們確實很高興看到全線的訂單強勁。這是——相當少見的一個季度,每一個事業都看到一致的訂單成長。所以那真的很棒。而以全年來看,我認為也相當強勁。
As we look at 2025 guidance, I guess what I would say is we'll expect PDx growth, broadly speaking, in line with the growth of 2024. And then the rest of the business, we'll expect to see growth, broadly speaking, in line with the corporate average. So those are a couple of the dynamics.
就我們對 2025 年的指引來看,我想我會這麼說:我們預期 PDx 的成長,廣義而言,將與 2024 年的成長大致一致。至於其餘業務,我們預期其成長,廣義而言,將與公司平均水準大致一致。以上是其中幾個動態。
Pete mentioned the Flyrcado assumption embedded in PDx, but beyond that, I think a nice environment overall contributes to the growth profile that we'll lay out for next year.
Pete 提到 PDx 中內含的 Flyrcado 假設,但除此之外,我認為整體良好的環境也有助於我們將為明年提出的成長輪廓。
Matt Taylor - Analyst
Matt Taylor - Analyst
And can I just ask one follow-up on Flyrcado, talking about the $30 million. Can you just talk about the gating factors and how you expect reimbursement to evolve? And then the steps through actually getting on contract? Or is the need for hospitals to sort of [reach in] your referral patterns and where their capital is placed, is that a gating factor? Maybe just talk about how you think that evolves throughout the year.
我想就 Flyrcado 再追問一個問題,談到那 3,000 萬美元。你能談談關鍵的限制因素,以及你預期給付(reimbursement)將如何演變嗎?以及實際上要上合約的步驟?或者,醫院是否需要某種程度上在你們的轉診模式中「介入」,以及他們的資本配置落點,這是否也是限制因素?請談談你認為這在一年當中會如何演變。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. Thanks, Matt. So again, as we spoke a little bit about this at Investor Day and the midterm opportunity, again, we believe on this is $0.5 billion type of product to drug. And so that hasn't changed at all from that standpoint.
是的。謝謝,Matt。所以再次重申,正如我們在投資人日以及中期機會中稍微談到的,我們仍然相信這是一個約 5 億美元規模的產品(到藥物)。因此從這個角度來看,這點完全沒有改變。
As I mentioned just in the previous question, our launch preparations are well on track, which is a combination of sales force. It is reimbursement. It's also manufacturing scale-up. And all of those are on track.
如我在上一個問題中提到的,我們的上市準備進展非常順利,包含銷售團隊的配置。也包含給付。同時也包含製造擴產。而這些都在軌道上。
Keep in mind that with a radiopharmaceutical, which has a half-life, the typical way that we work our manufacturing structure is in partnerships with contract manufacturing organizations. Why would that be? Because you need to have them closer to the cluster of where the products are. So we actually have a selection of CMOs already set up that will be ready to produce right in the beginning.
請記得,放射性藥物有半衰期,因此我們通常的製造架構會採取與委託製造機構(CMO)的合作模式。為什麼?因為你需要讓它們更靠近產品使用的群聚區域。所以我們其實已經建立了一組 CMO 的選擇名單,能在一開始就準備好投入生產。
And we also then target our sales operations within those geographical areas. Why? Because you need to be able to deliver it within a half-life window within there. So that manages how fast you ramp. You go a little bit more methodically.
接著我們也會把銷售營運的重點放在那些地理區域內。為什麼?因為你必須能在半衰期的時間窗內完成交付。因此這會影響你擴張的速度。你會採取更有節奏、較為循序的方法。
We're also targeting centers that have cardiovascular PET capabilities already. Why? Because they're already doing these patients, in some cases, with Rubidium. this would give them better options as far as how they can actually implement it. And then we'll be working on adding additional capacity into other areas.
我們也會鎖定那些已具備心血管 PET 能力的中心。為什麼?因為他們已經在做這類病患,在某些情況下使用的是銣(Rubidium)。這將為他們在實際導入上提供更好的選項。接著我們也會在其他區域增加額外產能。
But other -- unlike other drugs where you can ship something, put it on the shelf and convert over time, remember, this is just-in-time delivery. So there's a little bit more orchestration to it. But this is what we do on other molecules day in and day out. So we feel good about it. But again, it's why we have a more measured approach as we roll that out.
但不同於其他藥物可以出貨、放上貨架再逐步轉換,請記得,這是即時(just-in-time)交付。所以需要更多的協調與調度。不過這正是我們在其他分子產品上日復一日所做的事。因此我們對此很有信心。但也正因如此,在推展時我們會採取更審慎、較為有節奏的方式。
To your point on coding and things, we're well down on the road on that. I'd say, from a coding and HCPCS codes and stuff, we're on track here to have approvals and fundamentally the code in effect in April.
就你提到的編碼等事項,我們在這方面已經走得很前面了。我會說,就編碼、HCPCS 代碼等,我們目前進度符合預期,目標是在 4 月取得核准,並讓代碼基本上生效。
We've also filed through pass-through we would expect to have that not too far off of that date, but we'll see when that comes in, but we feel really good about how this is playing out. And as I mentioned, our first commercial doses are going to be here not in the too far distant future.
我們也已經就 pass-through 提出申請,我們預期其時間點不會離上述日期太遠,但仍要看實際核發時間;不過我們對目前的進展非常有信心。而如我所提到的,我們的首批商業化劑量在不久的將來就會到來。
Operator
Operator
Joanne Wuensch, Citi.
Joanne Wuensch,花旗。
Joanne Wuensch - Analyst
Joanne Wuensch - Analyst
I will just put in both out there. One, could you just spend a moment on the first quarter, please? I'm trying to just pace through some of the year-over-year commentary on how to think about maybe some of the headwinds. I get the revenue headwinds, but I want to make sure I appreciate the op margin headwinds and what you're implying for year-over-year op margin expansion.
我把兩個問題一起提出。第一,能否請你花點時間談談第一季?我想把一些年對年(YoY)的評論串起來,理解該如何看待一些可能的逆風。我理解營收的逆風,但我想確認我也充分掌握營業利益率(op margin)的逆風,以及你們對年對年營業利益率擴張所暗示的內容。
And then second of all, if you could just sort of broadly, and this probably could take up the rest of the call, talk about the competitive landscape and what you're really seeing versus some of the other competitors that you participate in globally.
第二,如果可以的話,請你從更宏觀的角度——這可能可以講完整場電話會議——談談競爭格局,以及你們相較於其他全球同業競爭者實際看到的情況。
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Sure. So as we think about the first quarter, obviously, we're going to have a decline. And from a sales standpoint, we'll have a decline in China and then we'll have growth in the rest of the world. But I think from a P&L standpoint, really the noteworthy items relate to this investment that we've described.
當然。就第一季而言,顯然我們會出現下滑。從銷售角度看,中國會下滑,而世界其他地區會成長。但我認為從損益表(P&L)的角度,真正值得注意的項目與我們所描述的這些投資有關。
From both an R&D and SG&A standpoint, we will see a bit of growth in the first quarter in those categories. And so it will offset some of the expansion that we'll see from a gross margin standpoint, landing us to a flat number.
在研發(R&D)與銷售、一般及行政費用(SG&A)兩方面,第一季我們會看到這些類別有些許成長。因此它會抵銷我們在毛利率方面看到的部分擴張,使得最終落在一個持平的數字。
But as we go forward through the rest of the year, you start to get the benefit of some sales attached to the new products that we're launching, and some of the R&D investment moderates over time.
但隨著我們進入今年其餘時間,你會開始看到一些與我們正在推出的新產品相關的銷售貢獻帶來的好處,同時部分研發投資也會隨時間而趨於溫和。
And so really, it's not specific onetimers per se, but it's this imbalance between we want -- really want to make sure that we're investing for success on our way to driving the sales growth for the year. We want to make sure we're investing for success as we look to support the midterm with some of these new products. And so that's leading to the first quarter margin that you'll see.
因此這並非特定的一次性因素(onetimers),而是這種不平衡:我們希望——真的希望——確保我們在推動今年銷售成長的過程中,為成功進行投資。我們也希望在展望中期時,為成功進行投資,以支援其中一些新產品。因此這就導致你會看到第一季的利潤率表現。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
And then, Joanne, to your question on competitive nature and things, I would say, look, as you know, I would say there's similarities between many of the companies that we compete with, but there's no compositions between any of us that are the same, as you would know.
然後,Joanne,關於你問到的競爭性等,我會說,正如你所知,我認為我們與許多競爭對手之間有一些相似之處,但我們彼此之間沒有任何一家公司的產品組合是完全相同的,你也知道這點。
I mean, we're not in radiation treatment, some others aren't in monitoring. No one else really is in radiopharmaceutical drug development, similar to we are. So there's a lot of mix changes that play through there.
我的意思是,我們不做放射治療,有些公司不做監測。也沒有其他公司像我們一樣真正投入放射性藥物的藥物開發。所以其中會有很多組合變化的因素在發揮作用。
But I would say in the core imaging area where there is some commonality and things, we've done well across the globe. I think we've probably done a little bit better in the US than maybe we've done in Europe. Maybe some others have had some better experiences, one spot or the other, in those areas. I think that we've been able to take some share from certain players in the marketplace. I think that may be true for others as well. There's a mix that obviously always takes place.
但我會說,在核心影像領域——也就是存在一些共通性之處的地方——我們在全球表現不錯。我認為我們在美國的表現可能比在歐洲更好一些。也許有些同業在某些地區的經驗更好,或在其他地區更好。我認為我們已經從市場上的某些玩家手中取得了一些市占。我想其他公司可能也有類似情況。當然,市場上總是會發生組合變化。
But I would say one of the interesting things in a capital business where you have a large installed base and you talk about sales growth in a given window, and I'll just refer back to us like with Air Recon DL, we've made really good progress there.
但我會說,在資本設備型業務中,你有龐大的裝機基礎,當你談到某一段期間內的銷售成長時,其中一個有趣的點是——我就以我們自己為例,像 Air Recon DL,我們在那方面已經取得非常好的進展。
And we've actually taken some share, meaning new sockets that we didn't have. But the vast majority of that is converting our own installed base, which shows up in growth and share expansion by bringing new capabilities to those areas.
而且我們其實也拿到了一些份額,也就是我們過去沒有的新機台安裝點(new sockets)。但其中絕大多數是把我們自有的既有裝機基礎進行升級轉換;透過為這些領域帶來新的能力,這會反映在成長以及市占擴張上。
And I think for all of us, there's always windows of time where you're converting your own installed base faster. And if you're converting it with a product that costs twice or 3 times as much as what you have, you obviously have a higher sales growth during that period of time.
我想對我們所有人而言,總會有一些時間窗口,你會更快地把自家的既有裝機基礎轉換升級。而如果你是用一個成本是原來兩倍或三倍的產品來做轉換,那在那段期間你的銷售成長顯然會更高。
And we know when we introduce some of our products such as full body PET and some of the premium things in the area like Photon Counting, those ASPs will be significantly higher than what we're shipping today and you'll see some of that growth in dollars come through.
我們也知道,當我們推出一些產品,例如全身 PET,以及像光子計數(Photon Counting)這類高階產品時,這些平均售價(ASP)將會顯著高於我們今天出貨的產品,你也會看到其中一部分以金額計的成長反映出來。
When it comes to socket share like what you're holding on to in growth, we know we're doing well just from the reported share numbers and things in the marketplace. So hopefully, that helps a little bit with some added color.
至於像你提到的、在成長中維持的機台安裝點市占(socket share),從已公布的市占數據以及市場上的各種情況來看,我們知道我們做得不錯。希望這能提供一些額外的說明。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行(Wells Fargo)。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
Pete, maybe talk about the Sutter deal. $1 billion over seven years, is that linear or almost $150 million a year? And what are you assuming for 2025? And do you see similar opportunities elsewhere? And I had one follow-up.
Pete,能否談談 Sutter 這筆交易?7 年 10 億美元,這是線性認列、也就是每年接近 1.5 億美元嗎?你們對 2025 年的假設是什麼?你們是否在其他地方也看到類似機會?我還有一個追問。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, Larry, I'll start with the end of your question. We see lots of opportunity down the road, as you can imagine. Even when you announce things like this, you get calls from other folks and things. And we're really kind of getting our value stride together. And again, some of these structures in the past were more about if you buy a lot, you get a lower price.
好的,Larry,我先從你問題的最後一部分開始。如你所想,我們在未來看到很多機會。即使你宣布了這類事情,也會接到其他人的來電等等。而我們也正在把我們的價值主張步調整合起來。再說一次,過去有些架構比較像是「你買得多,就給你更低的價格」。
A big part of what we offer is if you work with us on this, we help you actually drive better productivity, better outcomes, better patient experience. And ultimately, then it's a win-win on both sides. And so we feel really good about it. I think the Nuffield Health in the UK is a good example as well. So expect to see more.
我們提供的一大部分價值在於:如果你和我們一起做這件事,我們會協助你實際提升生產力、改善結果、提升病患體驗。最終這會讓雙方都受益、達成雙贏。所以我們對此感覺非常好。我認為英國的 Nuffield Health 也是一個很好的例子。所以你可以期待看到更多。
With Sutter, like most of these, it's not always linear. And so it's not always just back-ended, it based on the account. I would say in a case like Sutter, which is all California-based and with the earthquake regs that exist, site renovations and changes are probably the longest lead item.
至於 Sutter,和多數這類案子一樣,它不一定是線性的。所以也不一定只是後段才放量,而是取決於該客戶的情況。我會說像 Sutter 這種案例,因為全部都在加州,而且有既有的地震法規,場址翻修與變更可能是前置期最長的項目。
So we'll see more of those things taking place in the mid-window time of the year. But I would also go to say that the orders for Sutter, those will be coming into our order book here in the first half of the year. We'll put some of those in and then each year thereafter.
因此我們會在一年當中的中段時間窗口看到更多這類事情發生。但我也要說,Sutter 的訂單會在今年上半年進入我們的訂單簿。我們會先放進其中一部分,之後每一年也都會持續。
So that's to come, but we feel really good about that opportunity, and again, the partnership that we can have with them to improve patient lives in Northern California.
所以這些都還在後面,但我們對這個機會感到非常好;同樣地,我們也很看好能與他們建立的合作夥伴關係,來改善北加州病患的生活。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
That's helpful. One more for you, Pete. It sounded like at JPMorgan that you expect to be more active on the M&A front in 2025. Is that fair? Are you still focused on tuck-in M&A? And any update on the areas of interest?
這很有幫助。再問你一個,Pete。聽起來你在摩根大通(JPMorgan)那邊提到,你們預期 2025 年在併購(M&A)方面會更積極。這樣理解公平嗎?你們仍然聚焦在補強型併購(tuck-in M&A)嗎?以及關注領域有沒有更新?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, Larry, I think for us, we believe that tuck-in M&A is superimportant. I think tuck-in M&A can be of various sizes, right? They can be larger, they can be smaller. The key is that they have a very strong strategic fit and they fit into our financial returns framework.
是的,Larry,我想對我們而言,我們相信補強型併購非常重要。我認為補強型併購可以有不同規模,對吧?可以更大,也可以更小。關鍵在於它們必須具有非常強的策略契合度,並且符合我們的財務報酬框架。
And I think we've -- Jay and I have a cadence weekly. We have a strategic cadence that happens multiple times a month with our business teams looking at what we're solving for with organic investments and what makes the most sense with inorganic.
而且我想我們——Jay 和我——每週都有固定節奏的討論。我們也會在每個月多次,和事業團隊以策略節奏檢視:在有機投資上我們要解決什麼問題,以及哪些地方用無機方式最合理。
And as we change our lens, again, to be more than just an imaging company, be much more health care solutions company, you start looking longitudinally at things you can plug in to bring more value. And again, as we meet with customers like Sutter, they're looking for how do you not just solve point solutions, how does this all connect together.
當我們再次調整視角,不再只是影像公司,而是更像一家醫療照護解決方案公司時,你就會以更長期的角度去看有哪些東西可以接進來、帶來更多價值。同樣地,當我們與像 Sutter 這樣的客戶會面時,他們在找的是:你如何不只是解決單點方案,而是讓這一切彼此串接起來。
And so M&A will play an important part of that and we're optimistic here in 2025, and honestly, into 2026 with a strong balance sheet, the cash flow generation that we have that M&A can be a more healthy participation into our play.
因此,併購會在其中扮演重要角色;我們對 2025 年感到樂觀,坦白說延伸到 2026 年也是如此。
The NMP deal that we announced in the fall, which really gives us a beachhead for radiopharmaceutical manufacturing and capabilities in Japan and also outside of Japan into Southeast Asia, that's another great example of taking a capability now with the new molecules coming and kind of having in each region of the world, Europe, US and Asia, having a radiopharmaceutical capability.
我們在秋季宣布的 NMP 交易,確實讓我們在日本的放射性藥物製造與能力上建立了灘頭堡,並且也能從日本延伸到東南亞。
So again, examples like that, that plug into our strategy that makes sense, expect to see more.
所以,再次強調,像那樣能夠嵌入我們策略、且合理的案例,你可以期待看到更多。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛(Goldman Sachs)。
David Roman - Analyst
David Roman - Analyst
I wanted just to start on the AVS business here for a second. Pete, you made a reference in your prepared remarks to some of the benefits you're seeing in that category tied to select procedure volume growth.
我想先花一點時間談談 AVS 業務。Pete,你在事先準備的發言中提到,你在該類別看到一些好處,與特定手術量(procedure volume)的成長有關。
But can you maybe help us understand sort of the inflection point that you saw in that business this quarter with respect to growth and how we should think about the underlying drivers there on a go-forward basis?
但你能否幫我們理解一下,本季你在該業務上看到的、相對於成長的拐點是什麼?以及往後我們應該如何看待其背後的驅動因素?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, David. So in AVS, again, just to remind everybody, the biggest chunks of that are our large ultrasound business and then also interventional labs, so cath labs, surgical and stuff. And so we saw ultrasound actually have a very good quarter overall.
好的,David。在 AVS 方面,再提醒大家一下,其中最大宗的是我們的大型超音波業務,另外還有介入式實驗室,也就是導管室(cath labs)、手術等。因此我們看到超音波整體而言本季表現非常好。
Some of that is tied to our new platforms that were launched early last year that we're getting traction. And again, still with a pressured China market. And so throughout other areas within the world, we actually did quite well within that base.
其中一部分與我們去年年初推出的新平台有關,目前正在取得市場動能。同時,中國市場仍然承壓。因此在全球其他地區,我們在這個基礎盤上其實表現相當不錯。
We also have some new launches and things coming this year, more so later in the second half within the cardiovascular side, which we're quite excited about and think that's going to continue to drive it.
我們今年也會有一些新產品上市,更多會落在心血管領域,時間點偏向下半年後段;我們對此相當興奮,也認為這將持續帶動成長。
But specifically, our cath lab, the Allia IGS Pulse just has exceeded expectations. I think we're talking to customers that candidly probably wouldn't have a dialogue with us in the past relative to the performance of our lab.
但具體來說,我們的導管室產品 Allia IGS Pulse 的表現已經超出預期。我想我們正在與一些客戶對話,坦白說,過去他們可能不會因為我們實驗室的表現而願意和我們談。
Some of that is the output to do bariatric patients, get views from a cardiac procedures that you can't, radiation efficiency for someone who's going to be in the lab for a structured heart for long cases. And they're seeing a premium lab that's really one of the TOP 1 or TOP 2 out in the marketplace. So we're seeing the orders come in from that standpoint.
其中一部分在於:它能支援肥胖病患(bariatric patients)的成像輸出、在心臟手術中取得你以往做不到的視角;對於需要在導管室進行長時間結構性心臟(structural heart)長案例的情況,也具備更好的輻射效率。而他們看到的是一個高階導管室系統,確實是市場上前 1 或前 2 名的產品。因此從這個角度,我們看到訂單正在進來。
And then on the surgical side, OEC, which has been a very strong brand worldwide, with the growth in surgery centers and the movement of more orthopedic procedures out there, you need to have a high-quality surgical C-arm. You need to have ultrasound like our LOGIQ. All of those are doing very well because of that.
接著在外科端,OEC 作為全球非常強勢的品牌,隨著手術中心的成長,以及更多骨科手術移轉到那裡進行,你就需要一台高品質的外科 C 形臂。你也需要像我們 LOGIQ 這樣的超音波。因為這些因素,這些產品的表現都非常好。
And you may recall, we migrated what we call OEC 3D capabilities onto that lab in the outpatient center. And so as more of these sophisticated procedures go there, our OEC C-arm has, in many cases, procedures that were only tied to fixed C-arms in the past. So that's been growing significantly fast as well. And we would expect those trends to continue here as we get into '25.
你可能還記得,我們把所謂的 OEC 3D 功能移植到門診中心的那個導管室。因此,隨著更多這類高階手術在那裡進行,我們的 OEC C 形臂在許多情況下,已能支援過去只能依賴固定式 C 形臂的手術。所以這塊也在顯著且快速地成長。而且我們預期,進入 2025 年後這些趨勢仍會延續。
David Roman - Analyst
David Roman - Analyst
That's very helpful perspective. And Jay, maybe I'm trying to piece together some of the moving parts here on the free cash flow side. You referenced in your prepared remarks inventory being a headwind here. But as I look through the cash flow that you disclosed, it looks like inventory was actually down year-over-year. You saw a benefit in accounts payable year-over-year.
這個觀點很有幫助。Jay,我想我正在把自由現金流這邊的一些變動因素拼湊起來。你在事先準備的發言中提到,庫存在這裡是一個逆風。但我看你們揭露的現金流,庫存其實是年對年下降。而應付帳款年對年則帶來了助益。
So I was just trying to understand the factors influencing the declines in free cash flow here and why that reverses in 2025.
所以我只是想了解,哪些因素導致自由現金流在這裡下滑,以及為什麼在 2025 年會反轉。
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Yeah. I think, David, the miss on 2024, as we looked at our expectations, really comes down to an inventory build that occurred in the latter part of the year. Some of that was strategic inventory levels. Some of it was we have further optimization opportunity in terms of how we manage inventory. It's an opportunity for improvement for us. We saw some sales volatility in specific categories, which makes it tough for careful inventory planning.
是的。David,我認為 2024 年未達我們原先預期,主要是因為在年底後段出現了庫存增加。其中一部分是策略性庫存水位。另一部分是我們在庫存管理方式上仍有進一步優化的空間。這對我們來說是改善機會。我們也在某些特定品類看到銷售波動,這讓精準的庫存規劃變得更困難。
And so as I look at the inventory balance as we sit here today, we really do see an opportunity moving into next year. Optimizing inventory, we should see some turns improvement next year. We should see operational working capital overall improve through a lot of the lean measures that we're focused on. But this is a -- it's an opportunity for us. I would say that some of the performance will benefit next year from the drawdown of inventory levels that are inflated at this point in time.
因此,當我看我們目前的庫存餘額時,確實看到明年有機會。透過優化庫存,我們明年應該會看到周轉率有所改善。我們也應該會透過我們聚焦的多項精實措施,讓整體營運周轉資金改善。但這是一個——對我們而言的改善機會。我會說,明年的部分表現將受惠於把目前偏高的庫存水位拉回(去化)。
Operator
Operator
Robbie Marcus, JPMorgan.
JPMorgan 的 Robbie Marcus。
Robbie Marcus - Analyst
Robbie Marcus - Analyst
Maybe first on the capital equipment market outlook. Given all the pressures we're seeing with hospitals in the US, how are you feeling about the outlook here? And what's the assumption on the capital market, including guidance?
先談資本設備市場展望。考量到我們在美國看到醫院面臨的各種壓力,你們對這裡的展望感受如何?另外,對資本市場的假設是什麼(包含在指引中)?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, Robbie, as I was mentioning, I think when you take a look at the underlying procedure growth and the ability to execute on the procedure growth, particularly on the interventional products we mentioned, the need to actually leverage obviously ultrasound and multiple points of care, we feel pretty good about it. And I think as we've done different surveys with customers and such, we think that's out there.
是的,Robbie,如我剛才提到的,我認為當你看底層的手術量成長,以及把手術量成長落地執行的能力,特別是我們提到的介入性產品;再加上確實需要運用超音波以及多個照護場域(point of care),我們對此感覺相當不錯。而且我們也做了不同的客戶調查等,我們認為需求確實存在。
I think, obviously, there's a lot of open questions about how certain reimbursement changes, either it be inpatient or outpatient rates or what plays out with certain drug reimbursement programs that are out there. But we're not seeing, at this point in time, I would say people put the brakes on in anticipation of any type of change.
我想,當然仍有很多未解問題,例如某些給付(reimbursement)變動——不論是住院或門診費率,或是某些藥品給付計畫最終會如何發展。但就目前而言,我不會說我們看到大家因為預期任何變動而踩煞車。
I would also say that, particularly in our core capabilities, which is the MR and CT and MI world, ultrasound, many of those products, even in worlds where it's a tighter CapEx environment and it's a tighter cost environment, tend to be accelerators to generate profit for the institution. And so, we haven't seen a lot of signs of that. But at this point in time, we're still seeing a pretty robust capital market estimates for the US.
我也會說,特別是在我們的核心能力——也就是 MR、CT、MI(分子影像)領域,以及超音波——許多這些產品,即使在資本支出環境更緊、成本環境更緊的情況下,往往仍是能加速為機構創造利潤的工具。因此,我們沒有看到太多那方面的跡象。但就目前而言,我們仍看到美國資本市場的預估相當強勁。
And then as I mentioned, for Europe, where it was a little bit slower in the second half of the year last year, we're expecting to see somewhat of a pickup but not to the same level we're seeing in the US.
另外如我提到的,歐洲去年下半年稍微慢一些,我們預期會有些回升,但不會達到我們在美國看到的同樣水準。
Jay, what would you add?
Jay,你會補充什麼?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
No, I think that's right. And Robbie, we've talked in the past about the survey work that we do on a quarterly basis with our major customers. And everything that we're seeing is pointing to a continued robust environment. We'll watch very carefully how things evolve and how policy initiatives impact this. But as of now, the environment seems solid.
沒有,我認為這說得對。Robbie,我們過去談過,我們每季都會對主要客戶做調查研究。我們看到的一切都指向環境將持續強勁。我們會非常謹慎地觀察事情如何演變,以及政策倡議會如何影響這一切。但截至目前,環境看起來很穩健。
Robbie Marcus - Analyst
Robbie Marcus - Analyst
Great. Maybe a quick follow-up. Jay, free cash flow was down year-over-year. What was the reason for that in '24? And how do we think about that in '25?
很好。也許快速追問一下。Jay,自由現金流年對年下降。2024 年的原因是什麼?那 2025 年我們該如何看待?
James Saccaro - Chief Financial Officer
James Saccaro - Chief Financial Officer
Yeah. The key driver of the reduction in free cash flow relates to inventory. We did have some strategic inventory build as we ended the year and we also have some optimization opportunities in terms of how we manage that.
是的。自由現金流下降的關鍵驅動因素與庫存有關。我們在年底確實做了一些策略性的庫存增加,同時在管理方式上也有一些優化機會。
A lot of this comes down to sales and operations planning and making sure there's an incredibly tight link between sales forecast and what you make, and there's opportunity there. And so I expect this will normalize over the course of the year and we will see some improvement in turns through next year, which is the catalyst for the growth in free cash flow year-over-year.
這很大一部分取決於銷售與營運規劃(S&OP),並確保銷售預測與生產之間有極其緊密的連結,而這方面存在改善空間。因此我預期,這會在今年逐步回歸正常,我們也會在明年看到周轉率有所改善,而這將成為自由現金流年對年成長的催化劑。
Operator
Operator
That concludes the question-and-answer session. Please proceed with any closing remarks.
問答環節到此結束。請進行任何結語。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. Thanks, everyone, for joining us today. Look forward to connecting with you in the coming days at one of our upcoming conferences. That concludes our call. Thank you very much.
好的。感謝各位今天加入我們。期待在接下來幾天於我們即將參加的其中一場會議上與各位交流。本次電話會議到此結束。非常感謝。
Operator
Operator
Ladies and gentlemen, thank you for your participation in today's conference. This does conclude today's presentation. You may now disconnect, and have a wonderful day.
各位女士、先生,感謝您參與今天的會議。今天的簡報到此結束。您現在可以掛線,祝您有美好的一天。